Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)

NCT04859517 is registered in ClinicalTrials.gov with Invivyd, Inc. as lead sponsor.

NCT NCT04859517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
Lead sponsor
Invivyd, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
April 27, 2021
Completion date
November 4, 2022
Enrollment
2,582 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19